In their manuscript, “The mixed-lineage kinase inhibitor URMC-099 protects hippocampal synapses in experimental autoimmune encephalomyelitis”, Bellizzi and colleagues investigated the possible neuroprotective effects of a mixed lineage kinase (MLK) inhibitor (URMC-099), developed by their research group, in an experimental model of MS. Here, MAP3K13 is linked to myeloid sarcoma.